

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Sarah Anne ROBERTSON *et al.*

Confirmation No.: 2475

Application No.: 09/380,327

Art Unit: 1644

Filed: September 3, 1999

Examiner: Michail A. Belyavskyi

For: TREATMENT AND DIAGNOSIS OF INFERTILITY USING TGF β OR ACTIVIN

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.

TIMING/FEE

This submission is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR § 1.114, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to


charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: March 30, 2006

Heller Ehrman LLP
1717 Rhode Island Avenue, N.W.
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

A handwritten signature in cursive script, reading "Patricia D. Granados", written over a horizontal line.

Patricia D. Granados
Reg. No. 33,683
Attorney for Applicants

Customer I.D. No. 26633

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/380,327
Filing Date	September 3, 1999
First Named Inventor	Sarah Anne ROBERTSON et al.
Group Art Unit	1644
Examiner Name	M.A. Belyavskyi
Attorney Docket Number	38530-0100US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A01	Immunity's Pregnant Pause, Nature, November 21, 2002, pp. 265-266, Vol. 420	
	A02	Gentle Persuasion, New Scientist, February 9, 2002, pp. 32-35,	
	A03	ANIE PHILIP et al., "Interaction of Transforming Growth Factor- β 1 with α ₂ -Macroglobulin", The Journal of Biological Chemistry, November 25, 1991, pp. 22290-22296, Vol. 266, No. 33	
	A04	LAIAGE M. WAKEFIELD et al., "Recombinant Latent Transforming Growth Factor β 1 Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor β 1, and a Different Tissue Distribution", The Journal of Clinical Investigation, Inc., December 1990, pp. 176-1984, Vol. 86	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.